160 related articles for article (PubMed ID: 21764327)
1. Intra-individual variability over time in serum cytokine levels among participants in the prostate, lung, colorectal, and ovarian cancer screening Trial.
Hofmann JN; Yu K; Bagni RK; Lan Q; Rothman N; Purdue MP
Cytokine; 2011 Nov; 56(2):145-8. PubMed ID: 21764327
[TBL] [Abstract][Full Text] [Related]
2. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Hofmann JN; Yu K; Horst RL; Hayes RB; Purdue MP
Cancer Epidemiol Biomarkers Prev; 2010 Apr; 19(4):927-31. PubMed ID: 20332255
[TBL] [Abstract][Full Text] [Related]
3. Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
Trabert B; Eldridge RC; Pfeiffer RM; Shiels MS; Kemp TJ; Guillemette C; Hartge P; Sherman ME; Brinton LA; Black A; Chaturvedi AK; Hildesheim A; Berndt SI; Safaeian M; Pinto L; Wentzensen N
Int J Cancer; 2017 Feb; 140(3):600-610. PubMed ID: 27770434
[TBL] [Abstract][Full Text] [Related]
4. Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.
Shikany JM; Flood AP; Kitahara CM; Hsing AW; Meyer TE; Willcox BJ; Redden DT; Ziegler RG
Cancer Causes Control; 2011 Jul; 22(7):995-1002. PubMed ID: 21553078
[TBL] [Abstract][Full Text] [Related]
5. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
[TBL] [Abstract][Full Text] [Related]
6. Cigarette smoking and variations in systemic immune and inflammation markers.
Shiels MS; Katki HA; Freedman ND; Purdue MP; Wentzensen N; Trabert B; Kitahara CM; Furr M; Li Y; Kemp TJ; Goedert JJ; Chang CM; Engels EA; Caporaso NE; Pinto LA; Hildesheim A; Chaturvedi AK
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25274579
[TBL] [Abstract][Full Text] [Related]
7. Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson's disease.
Lasseter HC; Provost AC; Chaby LE; Daskalakis NP; Haas M; Jeromin A
Cytokine X; 2020 Jun; 2(2):100027. PubMed ID: 33604555
[TBL] [Abstract][Full Text] [Related]
8. Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma.
Henry CJ; Sedjo RL; Rozhok A; Salstrom J; Ahnen D; Levin TR; D'Agostino R; Haffner S; DeGregori J; Byers T
BMC Cancer; 2015 Mar; 15():123. PubMed ID: 25884547
[TBL] [Abstract][Full Text] [Related]
9. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
O'Grady TJ; Kitahara CM; DiRienzo AG; Boscoe FP; Gates MA
PLoS One; 2014; 9(9):e106880. PubMed ID: 25192282
[TBL] [Abstract][Full Text] [Related]
10. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
[TBL] [Abstract][Full Text] [Related]
11. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years.
Simpson NK; Johnson CC; Ogden SL; Gamito E; Trocky N; McGuire C; Martin J; Barrow S; Lamerato L; Flickinger LM; Broski KG; Engelhard D; Hilke C; Bonk J; Gahagan B; Gren LH; Childs J; Lappe K; Fouad M; Thompson J; Sullivan D;
Control Clin Trials; 2000 Dec; 21(6 Suppl):356S-378S. PubMed ID: 11189688
[TBL] [Abstract][Full Text] [Related]
12. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of serum IL-16 and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Moore A; Huang WY; Danforth K; Falk R; Meade A; Bagni R; Berndt SI
Cancer Causes Control; 2018 May; 29(4-5):455-464. PubMed ID: 29594819
[TBL] [Abstract][Full Text] [Related]
15. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Stallings FL; Ford ME; Simpson NK; Fouad M; Jernigan JC; Trauth JM; Miller DS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):379S-389S. PubMed ID: 11189689
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
[TBL] [Abstract][Full Text] [Related]
17. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
Hayes RB; Reding D; Kopp W; Subar AF; Bhat N; Rothman N; Caporaso N; Ziegler RG; Johnson CC; Weissfeld JL; Hoover RN; Hartge P; Palace C; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):349S-355S. PubMed ID: 11189687
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons.
Wong HL; Pfeiffer RM; Fears TR; Vermeulen R; Ji S; Rabkin CS
Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3450-6. PubMed ID: 19064561
[TBL] [Abstract][Full Text] [Related]
19. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Miller AB; Yurgalevitch S; Weissfeld JL;
Control Clin Trials; 2000 Dec; 21(6 Suppl):400S-406S. PubMed ID: 11189691
[TBL] [Abstract][Full Text] [Related]
20. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.
Grubb RL; Pinsky P; Prorok PC; Andriole GL
Eur Urol; 2015 Oct; 68(4):545-6. PubMed ID: 25959167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
